相关实验视频

Updated: Jul 2, 2026

Clinical Protocol of Producing Adipose Tissue-Derived Stromal Vascular Fraction for Potential Cartilage Regeneration
14:49

Clinical Protocol of Producing Adipose Tissue-Derived Stromal Vascular Fraction for Potential Cartilage Regeneration

Published on: September 29, 2018

42.1K

[在腰部疼痛患者中对口服冠状腺保护剂有效性的比较评估]

O A Shavlovskaya1, I D Romanov1, I A Bokova2

  • 1International university of restorative medicine, Moscow, Russia.

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
|August 5, 2025
PubMed
概括

与两种和单一成分药物相比,Chondroguard TRIO是一种三组分的冠状腺保护剂,显著降低了疼痛. 这种新配方对骨关节炎和腰部疼痛管理有希望,没有报告的副作用.

关键词:
这就是Chondroguard TRIO.顺德里二硫酸盐 顺德里二硫酸盐冠状体保护剂 冠状体保护剂葡萄糖胺硫酸盐是什么 葡萄糖胺硫酸盐腰部疼痛 腰部疼痛 腰部疼痛 腰部疼痛骨关节炎是一种关节炎.药物与制药之间的关系没有变质的II型原蛋白.

更多相关视频

Manual Therapy for a Chronic Non-Specific Low Back Pain Rat Model07:34

Manual Therapy for a Chronic Non-Specific Low Back Pain Rat Model

Published on: August 11, 2023

791
Biomechanical Changes Related to Low Back Pain: An Innovative Tool for Movement Pattern Assessment and Treatment Evaluation in Rehabilitation06:28

Biomechanical Changes Related to Low Back Pain: An Innovative Tool for Movement Pattern Assessment and Treatment Evaluation in Rehabilitation

Published on: December 13, 2024

651

相关概念视频

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...